- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00005902
Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
A Prospective Natural History Study of VHL Patients With CNS Hemangioblastomas
The purpose of this study is to learn more about the growth of brain and spinal cord tumors and cysts that develop in association with them in patients with von Hippel-Lindau disease. It will examine how fast the tumors grow and try to determine what factors (for example, puberty , pregnancy, menopause, blood proteins, etc.) affect their growth.
Patients between the ages of 8 and 75 years who are enrolled in NIH s study of von Hippel-Lindau disease may be eligible for this 5-year study. Participants will have magnetic resonance imaging (MRI) of the brain and spinal cord and a thorough neurological history and examination at the start of the study. A blood sample will be taken for analysis of factors (hormones or other proteins) that may predict tumor growth. Follow-up clinic visits every 6 months will include a physical and neurological examination, blood tests, and MRI scans of the brain and spine. If symptoms or tumor growth requires more frequent follow-up, scans will be done at 3-month intervals.
Surgical removal of brain and spinal cord tumors is currently the treatment of choice when these lesions cause neurological problems. A better understanding of which tumors are likely to grow and which will remain stable may help guide physicians in treatment decisions and avoid unnecessary procedures.
Study Overview
Status
Conditions
Detailed Description
Hemangioblastomas of the cerebellum, brainstem and spinal cord are frequent tumors in patients with von Hippel-Lindau (VHL) disease. Rarely, these lesions also affect the cerebrum. Patients often have multiple lesions, many of which are associated with cysts or syrinx. The current treatment for symptomatic lesions is surgical resection. Focused radiation is also being used in selected cases in an attempt to provide tumor control. The natural history of central nervous system (CNS) lesions in patients with VHL has not been addressed in a prospective study. It is not clear at which point these lesions will begin to grow, or develop cysts in the cerebellum or syrinx in the spinal cord, and systemic factors that influence tumor growth have not been identified. By identifying factors that predict or influence tumor progression or cyst development, we can more accurately recommend surgical or medical intervention at appropriate times and avoid unnecessary treatment for stable lesions. This study will collect prospective radiological and clinical data on growth of the central nervous system (CNS) hemangioblastomas and associated cysts. We will also prospectively collect information on systemic processes that may influence tumor progression, such as puberty, menopause, pregnancy, effects of hormone therapy, tumor load, serum erythropoeitin level and hemoglobin/hematocrit levels.
This natural history study has resulted in significant improvement in our understanding of the pathophysiology of VHL disease. Data from this study have resulted in a better understanding of the origin and growth patterns of hemangioblastomas, and endolymphatic sac tumors in patients with VHL disease. New therapies targeting hemangioblastomas in VHL disease are being devised based on information gathered from this study. We expect this natural history disease to continue to inspire new hypothesis driven studies while improving the understanding and management of hemangioblastomas in VHL disease.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
INCLUSION CRITERIA:
- Ages 8-75.
- Confirmed diagnosis of von Hippel-Lindau disease.
- Presence of one or more cerebral, cerebellar or spinal cord hemangioblastomas on screening MRI.
- Able to give informed consent (or assent), or have a parent able to provide informed consent if a child.
- Karnofsky Performance Scale Score greater than or equal to 60.
- Have the capacity to undergo serial MRI scanning of the CNS without IV sedation.
EXCLUSION CRITERIA:
- Clinically unstable condition.
- Being treated by any chemotherapy, immunotherapy, or steroids.
- Allergy to CT or MRI contrast agents.
- Contraindication to MRI scanning such as surgery that involves metal clips or wires which might be expected to cause tissue damage or produce image artifacts.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
1
250 subjects with von Hippel-Lindau (VHL) disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the course of clinical and radiographic progression of VHL
Time Frame: Baseline, 12-24 month intervals
|
The questions to be answered fall in the following general categories: 1. Course of Clinical Progression 2. Radiographic Progression 3. Post-treatment outcome (surgery and radiation) 4. Contributing factors 5. Genetic variability and effects on disease progression
|
Baseline, 12-24 month intervals
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the course of tumor and cyst growth after surgical and/or radiation intervention.
Time Frame: 12 24 months after surgery until withdrawal or death
|
12 24 months after surgery until withdrawal or death
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prashant Chittiboina, M.D., National Institute of Neurological Disorders and Stroke (NINDS)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Hemangioma
- Neoplasms, Vascular Tissue
- Abnormalities, Multiple
- Neurocutaneous Syndromes
- Ciliopathies
- Angiomatosis
- Hemangioma, Capillary
- Von Hippel-Lindau Disease
- Hemangioblastoma
Other Study ID Numbers
- 000140
- 00-N-0140
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemangioblastoma
-
Assistance Publique Hopitaux De MarseilleCompletedHemangioblastoma (HB) of the Central Nervous System (CNS)France
-
Novartis PharmaceuticalsCompletedVon Hippel-Lindau Disease | Retinal Hemangioblastoma | CNS HemangioblastomaUnited States
-
Assistance Publique - Hôpitaux de ParisAgence Générale des Equipements et Produits de SantéRecruitingVon Hippel-Lindau Disease | Hemangioblastoma of CNSFrance
-
National Eye Institute (NEI)Active, not recruitingVon Hippel-Lindau Disease | Retinal HemangioblastomaUnited States
-
Dartmouth-Hitchcock Medical CenterGenentech, Inc.TerminatedVon Hippel Lindau Disease | HemangioblastomasUnited States
-
National Institute of Neurological Disorders and...CompletedVon Hippel-Lindau DiseaseUnited States
-
University Medical Center GroningenVHL AllianceCompletedRenal Cell Carcinoma | Von Hippel-Lindau Disease | Pheochromocytoma | Pancreatic Neuroendocrine Tumor | HemangioblastomaNetherlands
-
Memorial Sloan Kettering Cancer CenterPfizer; Dana-Farber Cancer Institute; University of Pittsburgh; University of VirginiaCompletedNeurofibromatosis | Meningioma | CNS Cancer | Hemangioblastoma | Intracranial HemangiopericytomaUnited States
-
European Organisation for Research and Treatment...RecruitingGlioma | Ependymoma | Hemangiopericytoma | Diffuse Midline Glioma, H3 K27M-Mutant | Germ Cell Tumor | Embryonal Tumor | Hemangioblastoma | Glioneuronal Tumor | Choroid Plexus Tumor | Pineal Tumors | Tumor of the Sellar Region | Pineal Tumor | Melanocytic Tumor of CNSSpain
-
Weill Medical College of Cornell UniversityNovartis PharmaceuticalsRecruitingPituitary Adenoma | Medulloblastoma | Meningioma | Esthesioneuroblastoma | Paraganglioma | CNS Tumors | HemangioblastomaUnited States